Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue
Public ClinicalTrials.gov record NCT01150981. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Effect of Rosiglitazone on In-vivo Angiogenic Potential of Human Adipose Tissue
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Insulin resistance is a common condition that can lead to type 2 diabetes. One of the commonly prescribed diabetes medications, called rosiglitazone, works by decreasing insulin resistance. Rosiglitazone appears to work on fat cells. Animal studies suggest that rosiglitazone may work by increasing blood vessel growth in fat cells. The purpose of this research is to see if rosiglitazone also increases blood vessel growth in human fat cells. The investigators will compare results from before and after being on rosiglitazone for 6 weeks.
Study identification
- NCT ID
- NCT01150981
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 35 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2006
- Primary completion
- Mar 31, 2010
- Completion
- Mar 31, 2010
- Last update posted
- Mar 25, 2012
2006 – 2010
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UMass Medical School | Worcester | Massachusetts | 01655 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Metabolic Syndrome trials
Other public records listing Metabolic Syndrome. Sorted by last update posted; newest first. Not a recommendation.
- NCT07804680: This Study Will Evaluate Cardiorespiratory and Muscular Fitness to Examine Associations With Anthropometric Characteristics and Other Indicators of Cardiometabolic Risk Among Patients With or Without Autism Spectrum Disorder Recruiting
- NCT07797036: Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Not yet recruiting
- NCT07218653: Human Cerebrovascular Blood Flow and Sex Differences in Metabolic Syndrome Not yet recruiting
- NCT07669168: Health Ahead Comparative Effectiveness Study Recruiting
- NCT07646782: Human Observatory Study Recruiting
- NCT07625332: Pilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI) Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01150981, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 25, 2012 · Synced Sep 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01150981 live on ClinicalTrials.gov.